TFPI-2 Protects Against Gram-Negative Bacterial Infection

Area of Science:

• Immunology
• Microbiology
• Biochemistry

Background:

• Tissue factor pathway inhibitor-2 (TFPI-2) is known as an anticoagulant.
• TFPI-2 is widely expressed and secreted into the extracellular matrix.
• TFPI-2-derived peptides, like EDC34, show antimicrobial activity.

Purpose of the Study:

• To elucidate the antimicrobial mechanism of TFPI-2 C-terminal peptide EDC34.
• To investigate the role of TFPI-2 in host defense against bacterial pathogens.
• To explore the therapeutic potential of TFPI-2 in infectious diseases.

Main Methods:

• Investigated EDC34 binding to human immunoglobulins (IgG, IgA, IgE, IgM).
• Assessed the effect of EDC34-IgG interaction on complement factor C1q binding and classical pathway activation.
• Utilized murine models of bacterial infection (Pseudomonas aeruginosa, Escherichia coli) and endotoxin challenge.
• Analyzed TFPI-2 expression and C-terminal fragments in infected organs and cystic fibrosis patient sputum.

Main Results:

• EDC34 binds to IgG, IgA, IgE, and IgM, particularly enhancing IgG interaction with C1q.
• This binding boosts complement activation, increasing host defense against bacterial infections.
• TFPI-2 is upregulated in infected organs, and TFPI-2 deficient mice are more susceptible to Pseudomonas aeruginosa.
• Mouse TFPI-2 peptide VKG24 protects against Escherichia coli infection, and TFPI-2 fragments are found in cystic fibrosis sputum.

Conclusions:

• TFPI-2 mediates a novel antimicrobial mechanism through immunoglobulin binding and complement activation.
• TFPI-2 plays a crucial role in host defense against Gram-negative bacterial pathogens.
• TFPI-2 and its C-terminal peptides represent a potential therapeutic strategy for bacterial infections.